Omeros | OMER - Current Liabilities


Omeros reported $85.5M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Adma Biologics USD 69.54M 13.05M Dec/2025
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Gilead Sciences USD 11.81B 485M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Immunic USD 30.62M 539K Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Rockwell Medical USD 10.95M 259K Jun/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025